Patent Cliffs: What Happens When a Drug Patent Expires?

Abstract

This review explores the concept of "patent cliffs," a critical juncture in the pharmaceutical industry where the expiration of drug patents results in abrupt revenue losses for innovator companies. When blockbuster drugs lose patent protection, generic competitors rapidly enter the market with significantly lower-priced alternatives, causing sharp declines in brand drug sales. The study delves into the multifaceted implications of this phenomenon, examining its economic, regulatory, and strategic dimensions. It highlights the role of legislation such as the Hatch-Waxman Act in accelerating generic entry and discusses how regulatory frameworks both support generic competition and enable brand protection tactics. The review also evaluates pharmaceutical companies' strategic responses—including lifecycle management, authorized generics, mergers, and Rx-to-OTC switches—to extend product profitability. Importantly, the paper emphasizes how patent cliffs expose vulnerabilities in drug development pipelines and can either constrain or catalyze innovation. The analysis concludes by advocating for balanced policy reforms that protect innovation incentives while promoting market competition and public health access.